Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | HRH1 | P35367 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206312 | 1.00 | HTR2A (0.64) | HTR2AHRH1TDP1SLC6A2SLC6A4 | |
| SCHEMBL1206311 | 1.00 | HTR2A (0.64) | HTR2AHRH1TDP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL20238142 | 0.98 | TDP1 (0.65) | HTR2AHRH1TDP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL20238217 | 0.98 | TDP1 (0.65) | HTR2AHRH1TDP1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL28133965 | 0.98 | TDP1 (0.65) | HTR2AHRH1TDP1SLC6A2SLC6A4 | |
| SCHEMBL3174219 | 0.81 | AOC3 (0.50) | HTR2AHRH1TDP1AOC3GBA1 | |
| SCHEMBL3174209 | 0.81 | AOC3 (0.50) | HTR2AHRH1TDP1AOC3GBA1 | |
| SCHEMBL26921899 | 0.80 | CHRNA7 (0.46) | HTR2AHRH1TDP1SLC6A2SLC6A4 | |
| SCHEMBL4455539 | 0.78 | SIGMAR1 (0.48) | HTR2AHRH1TDP1SLC6A2SLC6A4 | |
| SCHEMBL4506098 | 0.78 | HTR2A (0.67) | HTR2AHRH1TDP1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113234081-A | Preparation method of pyrrolopyrazole derivative and DMDPEDA as urea | 东南大学 | 2021-08-10 | — | — | CN | claimed |
| US-9896451-B2 | Method for producing endo-9-azabicyclo[3.3.1]nonan-3-ol derivative | NIPPON SODA CO., LTD. (JP) | 2018-02-20 | — | — | US | claimed |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | claimed |
| EP-1838690-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | Devgen N.V. (BE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006066879-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | DEVGEN N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| US-20250163065-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2025-05-22 | — | — | US | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693536-A | Pyrrolotriazinone compound, pharmaceutical composition containing pyrrolotriazinone compound, preparation method and application of pyrrolotriazinone compound | 上海科技大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-110981707-B | Method for synthesizing chiral citronellal by isomerism of nerol or geraniol | 万华化学集团股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-3640242-B1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | HITGEN LTD (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-20230115176-A1 | Complement Modulators and Related Methods | RA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070043133-A1 | Polyurethane foams, processes for obtaining them and use of these foams | RHODIA POLYAMIDE INTERMEDIATES (FR) | 2007-02-22 | — | — | US | disclosed |
| CN-1849352-A | Polyurethane foam, production methods thereof and use of same | RHODIA POLYAMIDE INTERMEDIATES (FR) | 2006-10-18 | — | — | CN | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115176-A1 | Complement Modulators and Related Methods | C5, C9, C1QBP | HTR2A 2975/4885HRH1 812/4885TDP1 2971/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | HTR2A 2362/4885HRH1 673/4885TDP1 484/4885 |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | KCNA4, HCN4, KCNN4 | HTR2A 2253/4885HRH1 1277/4885TDP1 3033/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | HTR2A 2333/4885HRH1 1063/4885TDP1 4665/4885 |
| US-20250163065-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | GPR139, GPR132, GPR142 | HTR2A 890/4885HRH1 209/4885TDP1 3901/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | HTR2A 685/4885HRH1 159/4885TDP1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.